Effect of Qiangli Dingxuan Tablets in the Treatment of Peripheral Vertigo Caused by Vestibular Neuritis

ZHANG Lingjun; ZHANG Fufang; MA Jinju

doi:10.3969/j.issn.1004-437X.2026.12.030

Abstract：Objective To study the clinical effect of Qiangli Dingxuan Tablets in the treatment of peripheral vertigo caused by vestibular neuritis and its influence on vertigo symptoms and sleep quality.Methods A total of 148 patients with peripheral vertigo caused by vestibular neuritis admitted to Kaifeng 155th Hospital from January 2022 to January 2025 were prospectively selected.They were randomly divided into conventional group(74 cases,treated with betahistine)and combined group(74 cases,treated with Qiangli Dingxuan Tablets combined with betahistine).All patients were treated for 4 weeks.The clinical efficacy of the two groups of patients was compared,as well as the scores of dizziness handicap inventory(DHI),dizziness assessment rating scale(DARS),visual analogue scale(VAS),vestibular activity participation(VAP),Pittsburgh sleep quality index(PSQI),activity specific balance confidence(ABC)scale before treatment,2 weeks and 4 weeks after treatment.The incidence of adverse reactions during treatment and the recurrence rate after 6 months of follow-up were also compared between the two groups.Results The overall clinical efficacy rate of the combined group was higher than the conventional group(P＜0.05).At 2 and 4 weeks after treatment,the scores of physical,functional and emotional dimensions of DHI,DARS and VAS scores in both groups decreased compared with baseline,and were lower in the combined group(P＜0.05).After 2 and 4 weeks of treatment,PSQI and VAP scores of the two groups were reduced,while ABC scores were increased,the combined group showed lower PSQI and VAP scores and higher ABC scores(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).During the 6-month follow-up,no case was lost to follow-up in the combined group and one case was lost in the conventional group.The recurrence rate in the combined group was lower than that in the conventional group(P＜0.05).Conclusion Qiangli Dingxuan Tablets combined with betahistine can improve the clinical efficacy of patients with peripheral vertigo,effectively relieve vertigo symptoms,improve sleep quality and balance function,reduce the recurrence rate,and have good safety.